{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T03:35:47Z","timestamp":1783654547775,"version":"3.55.0"},"reference-count":41,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/100020908","name":"Pfizer France","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020908","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ther Adv Med Oncol"],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Haematological toxicities (anaemia, neutropenia and thrombocytopenia), a known class effect of poly-ADP ribose polymerase inhibitors (PARPi) may limit exposure to PARPi and therefore impact efficacy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>This study aimed to provide practical and detailed recommendations for the prevention and management of these toxicities in metastatic prostate cancer in the real world.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design:<\/jats:title>\n                    <jats:p>A national consensus study was performed using a modified Delphi methodology.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>A multidisciplinary steering committee of 9 French experts formulated and submitted 38 statements to the vote of 33 French healthcare professionals experienced in oncology and PARPi in prostate and\/or breast\/ovarian cancers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>All recommendations achieved a consensus. Before initiating PARPi, haematological disorders should be investigated and appropriate corrective measures implemented. The haemoglobin level should ideally be \u2a7e10\u2009g\/dl and a minimum delay of 4\u2009weeks should be respected after chemotherapy. Monitoring should be frequent for the first 3\u2009months of treatment, at least every 15\u2009days, and even more frequent in patients at high-risk of toxicity. In the event of symptomatic grade 2 or 3 anaemia, grade 2 or 3 thrombocytopenia and grade 3 neutropenia, PARPi treatment should be discontinued until return to grade 1. Transfusion may be considered in symptomatic grade 2 or 3 anaemia. Myelodysplastic syndrome\/acute myeloid leukaemia should be suspected in cases of cytopenia persisting beyond 4\u2009weeks or changes in the blood count after maintenance of an optimal therapeutic dose over the long term.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>These proposals complement existing recommendations to guide healthcare professionals in real-world practice, and so optimise metastatic prostate cancer patient\u2019s ability to maximally benefit from PARPi.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/17588359251367308","type":"journal-article","created":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T11:10:34Z","timestamp":1757761834000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":2,"title":["Prevention and management of PARP inhibitor-related haematological toxicities in prostate cancer: French expert opinion using the Delphi method"],"prefix":"10.1177","volume":"17","author":[{"given":"Oph\u00e9lie","family":"Cassuto","sequence":"first","affiliation":[{"name":"Medical Oncology and Haematology Department, Polyclinique Saint George, Nice, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romain","family":"Mathieu","sequence":"additional","affiliation":[{"name":"Urology Department, Centre Hospitalier Universitaire de Rennes, Rennes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carole","family":"Helissey","sequence":"additional","affiliation":[{"name":"Medical Oncology and Haematology Department, Saint-Joseph Hospital, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3132-7730","authenticated-orcid":false,"given":"Antonin","family":"Schmitt","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Georges Fran\u00e7ois Leclerc Cancer Centre, Dijon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lien","family":"Gobert","sequence":"additional","affiliation":[{"name":"Oncology Department, Institut de Canc\u00e9rologie Radioth\u00e9rapie Br\u00e9tillien, Centre Hospitalier Priv\u00e9 Saint-Gr\u00e9goire, Rennes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lo\u00efc","family":"Mourey","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Oncopole Claudius Regaud-IUCT, Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Jovenin","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Centre ICONE, Bezannes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Bouteleux","sequence":"additional","affiliation":[{"name":"Advanced Practice Nurse in Oncology and Haemato-oncology, Clinique de l\u2019Atlantique, Puilboreau, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6168-4942","authenticated-orcid":false,"given":"Florence","family":"Joly","sequence":"additional","affiliation":[{"name":"Medical Oncology, Clinical Research Department, Fran\u00e7ois Baclesse Cancer Centre, Unicaen University, 3 Av. du G\u00e9n\u00e9ral Harris, Caen 14000, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,9,13]]},"reference":[{"key":"e_1_3_4_2_2","unstructured":"Ferlay J Ervik M Lam F et al. Global cancer observatory: cancer today (version 1.1). Lyon France: International Agency for Research on Cancer https:\/\/gco.iarc.fr\/today\/ (2024 accessed 10 April 2025)."},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10061416"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.purol.2022.07.147"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bulcan.2024.05.008"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14030801"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz192"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01649"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01055-3"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00382-0"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/bju.16130"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.6_suppl.18"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2022485"},{"key":"e_1_3_4_14_2","unstructured":"EMA. LYNPARZA (olaparib)-SmPC https:\/\/www.ema.europa.eu\/fr\/documents\/product-information\/lynparza-epar-product-information_fr.pdf (2024 accessed 8 September 2025)."},{"key":"e_1_3_4_15_2","unstructured":"EMA. AKEEGA (niraparib\/ac\u00e9tate d\u2019abirat\u00e9rone)-SmPC https:\/\/www.ema.europa.eu\/fr\/documents\/product-information\/akeega-epar-product-information_fr.pdf (2024 accessed 8 September 2025)."},{"key":"e_1_3_4_16_2","unstructured":"EMA. TALZENNA (talazoparib)-SmPC https:\/\/www.ema.europa.eu\/fr\/documents\/product-information\/talzenna-epar-product-information_fr.pdf (2025 accessed 8 September 2025)."},{"key":"e_1_3_4_17_2","unstructured":"FDA. RUBRACA (Rucaparib)-SmPC https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/209115s004lbl.pdf (2020 accessed 8 September 2025)."},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60893-8"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30684-9"},{"key":"e_1_3_4_20_2","article-title":"1834P Exposure-efficacy analyses of talazoparib in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) in the TALAPRO-2 trial","volume":"34","author":"Azad AA","year":"2023","unstructured":"Azad AA, Lincha VR, Hadigol M, et al. 1834P Exposure-efficacy analyses of talazoparib in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) in the TALAPRO-2 trial. Ann Oncol 2023; 34: S992\u2013S993.","journal-title":"Ann Oncol"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1111\/jcpt.13349"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S147726"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15194904"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bulcan.2022.06.011"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2024.05.009"},{"key":"e_1_3_4_26_2","unstructured":"The French National Cancer Institute. Inhibiteurs de PARP: olaparib niraparib rucaparib talazoparib https:\/\/www.e-cancer.fr\/Expertises-et-publications\/Catalogue-des-publications\/Inhibiteurs-de-PARP-olaparib-niraparib-rucaparib-talazoparib (2022 accessed 23 April 2024)."},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2648.2000.t01-1-01567.x"},{"key":"e_1_3_4_28_2","unstructured":"HAS. \u00c9laboration de recommandations de bonne pratique-M\u00e9thode \u00abRecommandations par consensus formalis\u00e9\u00bb https:\/\/www.has-sante.fr\/upload\/docs\/application\/pdf\/2011-01\/guide_methodologique_consensus_formalise.pdf (2015 accessed 27 June 2024)."},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.42.0489"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000032829"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13595"},{"key":"e_1_3_4_32_2","first-page":"1","article-title":"Anemia in men with advanced prostate cancer: incidence, etiology, and treatment","volume":"6","author":"Nalesnik JG","year":"2004","unstructured":"Nalesnik JG, Mysliwiec AG, Canby-Hagino E. Anemia in men with advanced prostate cancer: incidence, etiology, and treatment. Rev Urol 2004; 6: 1\u20134.","journal-title":"Rev Urol"},{"key":"e_1_3_4_33_2","article-title":"1829P Exposure-safety analyses of talazoparib in combination of enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) in TALAPRO-2 trial","volume":"34","author":"Azad AA","year":"2023","unstructured":"Azad AA, Wang Y, Hadigol M, et al. 1829P Exposure-safety analyses of talazoparib in combination of enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) in TALAPRO-2 trial. Ann Oncol 2023; 34: S990.","journal-title":"Ann Oncol"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyad045"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-022-01167-6"},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.5062"},{"key":"e_1_3_4_37_2","article-title":"Management of anaemia and iron deficiency in patients with cancer: ESMO Clinical Practice Guidelines","volume":"29","author":"Aapro M","year":"2018","unstructured":"Aapro M, Beguin Y, Bokemeyer C, et al. Management of anaemia and iron deficiency in patients with cancer: ESMO Clinical Practice Guidelines. Ann Oncol 2018; 29: iv96\u2013iv110.","journal-title":"Ann Oncol"},{"key":"e_1_3_4_38_2","article-title":"Transfusion thresholds for guiding red blood cell transfusion","volume":"12","author":"Carson JL","year":"2021","unstructured":"Carson JL, Stanworth SJ, Dennis JA, et al. Transfusion thresholds for guiding red blood cell transfusion. Cochrane Database Syst Rev 2021; 12: CD002042.","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_4_39_2","volume-title":"An\u00e9mie et cancer","author":"AFSOS","year":"2021","unstructured":"AFSOS. An\u00e9mie et cancer, https:\/\/www.afsos.org\/wp-content\/uploads\/2018\/01\/An%C3%A9mie-et-cancer_AFSOS_2021.pdf (2021, accessed 8 September 2025)."},{"key":"e_1_3_4_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2024.11.007"},{"key":"e_1_3_4_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(20)30360-4"},{"key":"e_1_3_4_42_2","article-title":"Managing adverse effects associated with poly (ADP-ribose) polymerase inhibitors in ovarian cancer: a synthesis of clinical trial and real-world data","volume":"43","author":"Friedlander M","year":"2023","unstructured":"Friedlander M, Lee YC, Tew WP. Managing adverse effects associated with poly (ADP-ribose) polymerase inhibitors in ovarian cancer: a synthesis of clinical trial and real-world data. Am Soc Clin Oncol Educ Book 2023; 43: e390876.","journal-title":"Am Soc Clin Oncol Educ Book"}],"container-title":["Therapeutic Advances in Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17588359251367308","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/17588359251367308","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17588359251367308","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T22:33:07Z","timestamp":1777588387000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/17588359251367308"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":41,"alternative-id":["10.1177\/17588359251367308"],"URL":"https:\/\/doi.org\/10.1177\/17588359251367308","relation":{},"ISSN":["1758-8359","1758-8359"],"issn-type":[{"value":"1758-8359","type":"print"},{"value":"1758-8359","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9]]},"article-number":"17588359251367308"}}